Coeptis Therapeutics Holdings, Inc. (COEPW) 10-Year Financial Performance & Capital Metrics

COEPW • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutCoeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.Show more

Revenue $0
EBITDA -$9M +56.0%
Net Income -$11M +48.9%
EPS (Diluted) -5.65 +65.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -265.91% +43.0%
ROIC -171.34% +63.9%
Debt/Equity 0.36 +27.5%
Interest Coverage -25.38 +87.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 49.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM15.99%

EPS CAGR

10Y-

5Y-

3Y-

TTM37.81%

ROCE

10Y Avg-406.36%

5Y Avg-406.36%

3Y Avg-424.79%

Latest-212.17%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	30.76K	75K	0	0	0
Revenue Growth %	-	-	1.44%	-1%	-	-
Cost of Goods Sold+	0	964.22K	447.41K	1M	1M	1.04M
COGS % of Revenue	-	31.35%	5.97%	-	-	-
Gross Profit+	0	-933.46K	-372.41K	-1M	-1M	-1.04M
Gross Margin %	-	-30.35%	-4.97%	-	-	-
Gross Profit Growth %	-	-	0.6%	-1.69%	0%	-0.04%
Operating Expenses+	0	5.93M	13.67M	33.19M	20.49M	9.02M
OpEx % of Revenue	-	192.71%	182.31%	-	-	-
Selling, General & Admin	0	5.78M	13.67M	33.17M	13.82M	6.68M
SG&A % of Revenue	-	187.78%	182.31%	-	-	-
Research & Development	0	3.54K	0	20.89K	6.67M	2.33M
R&D % of Revenue	-	0.12%	-	-	-	-
Other Operating Expenses	0	148.19K	0	0	0	0
Operating Income+	0	-6.86M	-14.05M	-34.2M	-21.49M	-10.05M
Operating Margin %	-	-223.06%	-187.28%	-	-	-
Operating Income Growth %	-	-	-1.05%	-1.43%	0.37%	0.53%
EBITDA+	171.86K	-6.54M	-13.6M	-33.19M	-20.49M	-9.02M
EBITDA Margin %	-	-212.54%	-181.31%	-	-	-
EBITDA Growth %	-	-39.04%	-1.08%	-1.44%	0.38%	0.56%
D&A (Non-Cash Add-back)	171.86K	323.43K	447.41K	1M	1M	1.04M
EBIT	0	-9.01M	-13.26M	-37.36M	-21.16M	-10.48M
Net Interest Income+	0	-148K	-187K	-218.41K	-107.69K	-396.12K
Interest Income	0	0	0	0	0	0
Interest Expense	0	148.19K	187.13K	218.41K	107.69K	396.12K
Other Income/Expense	-2.23K	-2.29M	596.65K	-3.38M	224.59K	-822.92K
Pretax Income+	-2.23K	-9.16M	-13.45M	-37.57M	-21.27M	-10.88M
Pretax Margin %	-	-297.66%	-179.32%	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-2.23K	-9.16M	-13.45M	-37.57M	-21.27M	-10.88M
Net Margin %	-	-297.66%	-179.32%	-	-	-
Net Income Growth %	-	-4097.61%	-0.47%	-1.79%	0.43%	0.49%
Net Income (Continuing)	-2.23K	-9.16M	-13.45M	-37.57M	-21.27M	-10.88M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	682.06K
EPS (Diluted)+	-0.00	-36.86	-24.64	-52.57	-16.56	-5.65
EPS Growth %	-	-	0.33%	-1.13%	0.69%	0.66%
EPS (Basic)	-0.00	-36.86	-24.64	-52.57	-16.56	-5.65
Diluted Shares Outstanding	539.06K	468.75K	545.73K	714.78K	1.28M	1.92M
Basic Shares Outstanding	539.06K	468.75K	545.73K	714.78K	1.28M	1.92M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	505	224.75K	2.18M	3.94M	1.75M	1.05M
Cash & Short-Term Investments	505	202.97K	2.18M	3.79M	1.47M	532.88K
Cash Only	505	202.97K	2.18M	3.79M	1.47M	532.88K
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	21.79K	0	8.07K	38.98K	0
Days Sales Outstanding	-	258.51	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0
Total Non-Current Assets+	171.04K	75.73K	4.59M	3.97M	6.32M	7.86M
Property, Plant & Equipment	0	73.73K	31.85K	71.46K	108.88K	59.78K
Fixed Asset Turnover	-	0.42x	2.35x	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	2.55M	541.88K
Long-Term Investments	0	0	0	0	3.5M	5.69M
Other Non-Current Assets	171.04K	2K	4.55M	3.9M	158.33K	1.56M
Total Assets+	171.54K	300.48K	6.77M	7.92M	8.07M	8.91M
Asset Turnover	-	0.10x	0.01x	-	-	-
Asset Growth %	-	0.75%	21.52%	0.17%	0.02%	0.1%
Total Current Liabilities+	155.85K	5.28M	2.76M	1.82M	2.99M	4.51M
Accounts Payable	450	1.62M	134.09K	99.02K	1.42M	1.27M
Days Payables Outstanding	-	614.7	109.39	36.09	517.55	446.22
Short-Term Debt	152.64K	1.88M	2.42M	1.5M	1.01M	1.19M
Deferred Revenue (Current)	2.76K	1000K	0	0	0	0
Other Current Liabilities	0	0	0	0	555.95K	1.28M
Current Ratio	0.00x	0.04x	0.79x	2.16x	0.59x	0.23x
Quick Ratio	0.00x	0.04x	0.79x	2.16x	0.59x	0.23x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	164.72K	1.65M	1.29M	768.43K	528.13K
Long-Term Debt	0	150K	1.65M	150K	150K	150K
Capital Lease Obligations	0	14.72K	0	14.72K	61.18K	18.88K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	-1	0	1.13M	557.25K	359.25K
Total Liabilities	155.85K	5.44M	4.41M	3.11M	3.76M	5.04M
Total Debt+	152.64K	2.09M	4.08M	1.71M	1.22M	1.4M
Net Debt	152.14K	1.88M	1.9M	-2.08M	-244.91K	866.17K
Debt / Equity	9.73x	-	1.74x	0.36x	0.28x	0.36x
Debt / EBITDA	0.89x	-	-	-	-	-
Net Debt / EBITDA	0.89x	-	-	-	-	-
Interest Coverage	-	-46.30x	-75.06x	-156.57x	-199.57x	-25.38x
Total Equity+	15.69K	-5.14M	2.35M	4.8M	4.31M	3.87M
Equity Growth %	-	-328.77%	1.46%	1.04%	-0.1%	-0.1%
Book Value per Share	0.03	-10.97	4.31	6.72	3.36	2.01
Total Shareholders' Equity	15.69K	-5.14M	2.35M	4.8M	4.31M	3.19M
Common Stock	25K	2.52K	3.55K	1.96K	3.53K	212
Retained Earnings	-9.31K	-14.1M	-27.55M	-65.74M	-87.36M	-98.23M
Treasury Stock	0	0	-247.16K	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	682.06K

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-90.07K	-3.14M	-4.49M	-3.88M	-7.24M	-6.65M
Operating CF Margin %	-	-101.95%	-59.86%	-	-	-
Operating CF Growth %	-	-33.82%	-0.43%	0.14%	-0.87%	0.08%
Net Income	-2.23K	-9.16M	-13.45M	-37.57M	-21.27M	-10.88M
Depreciation & Amortization	0	323.43K	447.41K	1M	1.04M	1.04M
Stock-Based Compensation	0	0	1.9M	0	477.5K	1.1M
Deferred Taxes	0	0	5.34M	0	0	0
Other Non-Cash Items	-88.28K	3.03M	4.26M	33.25M	10.79M	2.21M
Working Capital Changes	450	2.66M	-2.98M	-550.34K	1.73M	-125.26K
Change in Receivables	0	-14.91K	21.79K	-8.07K	-30.9K	-234.74K
Change in Inventory	0	732.15K	-422.02K	0	0	0
Change in Payables	0	1.47M	-1.58M	-35.07K	1.32M	-149.94K
Cash from Investing+	0	-75.75M	-1.75M	0	0	0
Capital Expenditures	0	0	-1.75M	0	0	0
CapEx % of Revenue	-	-	23.33%	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	90.57K	2.9M	8.22M	5.49M	4.92M	5.71M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	90.57K	0	-50.9K	4.63M	200K	500K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-90.07K	-3.14M	-6.24M	-3.88M	-7.24M	-6.65M
FCF Margin %	-	-101.95%	-83.19%	-	-	-
FCF Growth %	-	-33.82%	-0.99%	0.38%	-0.87%	0.08%
FCF per Share	-0.17	-6.69	-11.43	-5.42	-5.64	-3.45
FCF Conversion (FCF/Net Income)	40.32x	0.34x	0.33x	0.10x	0.34x	0.61x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-14.24%	-	-572.16%	-1050.44%	-466.51%	-265.91%
Return on Invested Capital (ROIC)	-	-	-2118.9%	-735.8%	-474.95%	-171.34%
Gross Margin	-	-3034.54%	-496.55%	-	-	-
Net Margin	-	-29765.89%	-17932.37%	-	-	-
Debt / Equity	9.73x	-	1.74x	0.36x	0.28x	0.36x
Interest Coverage	-	-46.30x	-75.06x	-156.57x	-199.57x	-25.38x
FCF Conversion	40.32x	0.34x	0.33x	0.10x	0.34x	0.61x
Revenue Growth	-	-	143.82%	-100%	-	-

Frequently Asked Questions

Growth & Financials

Coeptis Therapeutics Holdings, Inc. (COEPW) reported $0.5M in revenue for fiscal year 2024.

Coeptis Therapeutics Holdings, Inc. (COEPW) grew revenue by 0.0% over the past year. Growth has been modest.

Coeptis Therapeutics Holdings, Inc. (COEPW) reported a net loss of $9.8M for fiscal year 2024.

Dividend & Returns

Coeptis Therapeutics Holdings, Inc. (COEPW) has a return on equity (ROE) of -265.9%. Negative ROE indicates the company is unprofitable.

Coeptis Therapeutics Holdings, Inc. (COEPW) had negative free cash flow of $8.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener